Vemurafenib
Specifications
918504-65-1CAS Number
850-250-7EC Number
N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamideIUPAC Name
C23H18ClF2N3O3SChemical Formula
489.9 g/molMolecular Weight
Vemurafenib; 918504-65-1; Zelboraf; PLX-4032; PLX 4032; RG7204; RG 7204; RO 5185426; vemurafenibum; N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide; RG-7204; 207SMY3FQT; Ro 51-85426; RO-5185426; RO-51-85426; CHEBI:63637; DTXSID50238710; 1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-; 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-; N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide; RefChem:57849; DTXCID00161201; L01XE15; BRAF(V600E) Kinase Inhibitor RO5185426; BRAF (V600E) kinase inhibitor RO5185426; 1029872-54-5; N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide; Vemurafenib (PLX4032, RG7204); Vemurafenib (PLX4032); N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide; N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide; MFCD18074504; C23H18ClF2N3O3S; PLX4032 (Vemurafenib); N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; NSC761431; Vemurafenib;PLX-4032; N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide; N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide; Zelboraf (TN); 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-; Vemurafenib [USAN]; Vemurafenib [USAN:INN]; UNII-207SMY3FQT; HSDB 8143; n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide; N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide; Vemurafenib (Standard); 3og7; VEMURAFENIB [MI]; 1415041-85-8; Vemurafenib; PLX4032; VEMURAFENIB [INN]; VEMURAFENIB [JAN]; VEMURAFENIB [VANDF]; VEMURAFENIB [MART.]; Vemurafenib (PLX4032)?; VEMURAFENIB [WHO-DD]; SCHEMBL298931; Vemurafenib (JAN/USAN/INN); GTPL5893; orb1219665; orb1223651; orb1298741; orb1305565; CHEMBL1229517; SCHEMBL29355460; SCHEMBL29356185; EX-A053; VEMURAFENIB [ORANGE BOOK]; WLZ5401; GPXBXXGIAQBQNI-UHFFFAOYSA-N; GLXC-90076; GLXC-90433; HMS3265M03; HMS3265M04; HMS3265N03; HMS3265N04; HMS3654P09; HMS3748G15; HMS5079B05; EX-A1335; BDBM50396483; EBC-17135; HB4285; HY-12057R; MSK165863; NSC800964; s1267; AKOS007930804; CCG-264883; CS-0216; DB08881; FV15248; ME-0096; NSC-761431; NSC-800964; PB11741; SDCCGSBI-0647659.P002; NCGC00250399-01; NCGC00250399-05; NCGC00250399-08; NCGC00250399-16; AC-25010; BP-44063; HY-12057; SY067868; NS00008103; SW218095-2; T8654; V1668; D09996; R-7204; AB01273970-01; AB01273970_03; EN300-23265091; Q423111; SR-01000941568; carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; SR-01000941568-1; BRD-K56343971-001-02-3; BRD-K56343971-001-05-6; BRD-K56343971-001-10-6; BRD-K56343971-001-12-2; BRD-K56343971-001-14-8; PLX4032,Vemurafenib, RG7204, RO5185426, Zelboraf; N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-; N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-propane-1-sulfonamide; propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amideSynonyms
